ZyVersa Therapeutics reported a net loss of $1.8 million for Q1 2026, improving from $2.3 million a year earlier, while focusing on capital raising and reducing expenses. The company is advancing two main drug candidates: IC 100, an inflammasome inhibitor targeting cardiometabolic conditions, with an IND filing planned for Q4 2026 and Phase 1 data expected in H1 2027; and VAR 200, a renal drug targeting FSGS and Alport syndrome, with a Phase 2a trial starting in H2 2026 and interim results by Q4 2026. ZyVersa highlighted recent industry validation of its lead candidate's market potential and regulatory clarity in renal drug development, but noted it needs additional financing to continue operations and meet milestones.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
